BACKGROUND: The efficacy of influenza vaccines may decline during years when the circulating viruses have antigenically drifted from those included in the vaccine. METHODS: We carried out a randomized, double-blind, placebo-controlled trial of inactivated and live attenuated influenza vaccines in healthy adults during the 2004-2005 influenza season and estimated both absolute and relative efficacies. RESULTS: A total of 1247 persons were vaccinated between October and December 2004. Influenza activity in Michigan began in January 2005 with the circulation of an antigenically drifted type A (H3N2) virus, the A/California/07/2004-like strain, and of type B viruses from two lineages. The absolute efficacy of the inactivated vaccine against both types of virus was 77% (95% confidence interval [CI], 37 to 92) as measured by isolating the virus in cell culture, 75% (95% CI, 42 to 90) as measured by either isolating the virus in cell culture or identifying it through real-time polymerase chain reaction, and 67% (95% CI, 16 to 87) as measured by either isolating the virus or observing a rise in the serum antibody titer. The absolute efficacies of the live attenuated vaccine were 57% (95% CI, -3 to 82), 48% (95% CI, -7 to 74), and 30% (95% CI, -57 to 67), respectively. The difference in efficacy between the two vaccines appeared to be related mainly to reduced protection of the live attenuated vaccine against type B viruses. CONCLUSIONS: In the 2004-2005 season, in which most circulating viruses were dissimilar to those included in the vaccine, the inactivated vaccine was efficacious in preventing laboratory-confirmed symptomatic illnesses from influenza in healthy adults. The live attenuated vaccine also prevented influenza illnesses but was less efficacious. (ClinicalTrials.gov number, NCT00133523.) 2006Massachusetts Medical Society
RCT Entities:
BACKGROUND: The efficacy of influenza vaccines may decline during years when the circulating viruses have antigenically drifted from those included in the vaccine. METHODS: We carried out a randomized, double-blind, placebo-controlled trial of inactivated and live attenuated influenza vaccines in healthy adults during the 2004-2005 influenza season and estimated both absolute and relative efficacies. RESULTS: A total of 1247 persons were vaccinated between October and December 2004. Influenza activity in Michigan began in January 2005 with the circulation of an antigenically drifted type A (H3N2) virus, the A/California/07/2004-like strain, and of type B viruses from two lineages. The absolute efficacy of the inactivated vaccine against both types of virus was 77% (95% confidence interval [CI], 37 to 92) as measured by isolating the virus in cell culture, 75% (95% CI, 42 to 90) as measured by either isolating the virus in cell culture or identifying it through real-time polymerase chain reaction, and 67% (95% CI, 16 to 87) as measured by either isolating the virus or observing a rise in the serum antibody titer. The absolute efficacies of the live attenuated vaccine were 57% (95% CI, -3 to 82), 48% (95% CI, -7 to 74), and 30% (95% CI, -57 to 67), respectively. The difference in efficacy between the two vaccines appeared to be related mainly to reduced protection of the live attenuated vaccine against type B viruses. CONCLUSIONS: In the 2004-2005 season, in which most circulating viruses were dissimilar to those included in the vaccine, the inactivated vaccine was efficacious in preventing laboratory-confirmed symptomatic illnesses from influenza in healthy adults. The live attenuated vaccine also prevented influenza illnesses but was less efficacious. (ClinicalTrials.gov number, NCT00133523.) 2006 Massachusetts Medical Society
Authors: R B Belshe; W C Gruber; P M Mendelman; I Cho; K Reisinger; S L Block; J Wittes; D Iacuzio; P Piedra; J Treanor; J King; K Kotloff; D I Bernstein; F G Hayden; K Zangwill; L Yan; M Wolff Journal: J Pediatr Date: 2000-02 Impact factor: 4.406
Authors: R B Belshe; P M Mendelman; J Treanor; J King; W C Gruber; P Piedra; D I Bernstein; F G Hayden; K Kotloff; K Zangwill; D Iacuzio; M Wolff Journal: N Engl J Med Date: 1998-05-14 Impact factor: 91.245
Authors: R B Belshe; W C Gruber; P M Mendelman; H B Mehta; K Mahmood; K Reisinger; J Treanor; K Zangwill; F G Hayden; D I Bernstein; K Kotloff; J King; P A Piedra; S L Block; L Yan; M Wolff Journal: J Infect Dis Date: 2000-03 Impact factor: 5.226
Authors: K L Nichol; P M Mendelman; K P Mallon; L A Jackson; G J Gorse; R B Belshe; W P Glezen; J Wittes Journal: JAMA Date: 1999-07-14 Impact factor: 56.272
Authors: W C Gruber; R B Belshe; J C King; J J Treanor; P A Piedra; P F Wright; G W Reed; E Anderson; F Newman Journal: J Infect Dis Date: 1996-06 Impact factor: 5.226
Authors: P Vanhems; Y Baghdadi; S Roche; T Bénet; C Regis; B Lina; O Robert; N Voirin; R Ecochard; S Amour Journal: Hum Vaccin Immunother Date: 2016 Impact factor: 3.452
Authors: Adrian J Reber; Jin Hyang Kim; Laura A Coleman; Sarah M Spencer; Jessie R Chung; Jufu Chen; Paul Gargiullo; Maria E Sundaram; Edward A Belongia; David K Shay; Jacqueline M Katz; Suryaprakash Sambhara Journal: J Infect Dis Date: 2016-08-28 Impact factor: 5.226
Authors: John J Treanor; H Keipp Talbot; Suzanne E Ohmit; Laura A Coleman; Mark G Thompson; Po-Yung Cheng; Joshua G Petrie; Geraldine Lofthus; Jennifer K Meece; John V Williams; Lashondra Berman; Caroline Breese Hall; Arnold S Monto; Marie R Griffin; Edward Belongia; David K Shay Journal: Clin Infect Dis Date: 2012-07-25 Impact factor: 9.079
Authors: T N Athmaram; Anil Kumar Singh; Shweta Saraswat; Saurabh Srivastava; Princi Misra; M Kameswara Rao; N Gopalan; P V L Rao Journal: J Ind Microbiol Biotechnol Date: 2012-12-18 Impact factor: 3.346